SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# Narnatumab

**Cat. No.:** HY-P99375

**CAS No.:** 1188275-92-4

**Target:** Others

**Pathway:** Others

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a $K_d$ of 32 pM. Narnatumab can be used for the research of cancer[1]. |
| **$IC_{50}$ & Target** | RON(MSPR)[1] |
| **In Vitro** | Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines[1].<br>Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line[1].<br>Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice[1].<br>Narnatumab exhibits terminal half-life ($t_{1/2}$=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1] |
| Dosage: | 2, 20, 60 mg/kg |
| Administration: | I.p. every 3 days for 36 and 18 days |
| Result: | Inhibited tumor growth in a dose-dependent manner. |

## REFERENCES

[1]. LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA